One Repatha Presentation Will Be Discontinued Next Month, Another in 2025
Amgen Inc. will discontinue the Repatha (evolocumab) Pushtronex system, an on-body infusor, on June 30, the company said April 12. Certain patients, however, may need to remain on that system, and the manufacturer says it will maintain inventory of it to meet their needs.
In addition to the 420 mg/3.5 mL single-dose Pushtronex, Repatha is available as a 140 mg/mL single-dose SureClick autoinjector and a 140 mg/mL single-dose prefilled syringe. The company is urging users to transition to the SureClick because it plans to discontinue the prefilled syringe in mid-2025.
© 2025 MMIT